Overview

Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide continued therapy with Denileukin diftitox (ONTAK) to patients who are currently on therapy and who have no other suitable treatment options, where therapy is requested by their physician.
Details
Lead Sponsor:
Eisai Inc.
Treatments:
Denileukin diftitox
Interleukin-2